Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USA - Report - MDSpire
Advertisement
Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USA
Clinical Report: Exploring the Social Determinants of Health in HS
Overview
This study investigates the impact of hidradenitis suppurativa (HS) on diverse racial and ethnic populations in the U.S., highlighting significant healthcare access barriers and the disease's burden on quality of life. Findings indicate that social drivers of health play a crucial role in shaping patient experiences and treatment outcomes.
Background
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that severely affects patients' quality of life and healthcare access. Understanding the social determinants influencing HS outcomes is essential for addressing disparities in care among different racial and ethnic groups. This study aims to fill knowledge gaps regarding HS's impact on diverse populations in the U.S.
Data Highlights
No specific numerical data was provided in the source material.
Key Findings
HS prevalence is significantly higher in Black and/or African American individuals compared to white individuals (296 vs 95 per 100,000).
Patients with HS experience substantial impacts on their quality of life, including stigma and relationship issues.
Financial and social barriers significantly hinder access to effective HS treatment.
Many patients resort to nonmedical remedies for managing HS flares.
Awareness of social drivers of health can improve healthcare interactions and outcomes for HS patients.
Clinical Implications
Healthcare providers should consider the social drivers of health when treating patients with HS to tailor interventions effectively. Addressing barriers such as financial constraints and access to transportation can enhance treatment adherence and patient outcomes.
Conclusion
The study underscores the importance of recognizing social determinants in managing hidradenitis suppurativa, particularly among diverse racial and ethnic groups. Improved understanding can lead to better healthcare strategies and outcomes for affected patients.
by Tarannum Jaleel, Raj Chovatiya, Elizabeth D. Bacci, Evangeline Pierce, Melissa L. Constantine, Julia R. Correll, Beth Mitchell, Dipak R. Patel, Brindley Brooks, Candrice Heath, Vivian Y. Shi
Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.